197 related articles for article (PubMed ID: 25607338)
1. The comparative effect of pioglitazone and metformin on serum osteoprotegerin, adiponectin and intercellular adhesion molecule concentrations in patients with newly diagnosed type 2 diabetes: a randomized clinical trial.
Esteghamati A; Azizi R; Ebadi M; Noshad S; Mousavizadeh M; Afarideh M; Nakhjavani M
Exp Clin Endocrinol Diabetes; 2015 May; 123(5):289-95. PubMed ID: 25607338
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of metformin and pioglitazone on fetuin-A and osteoprotegerin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial.
Esteghamati A; Afarideh M; Feyzi S; Noshad S; Nakhjavani M
Diabetes Metab Syndr; 2015; 9(4):258-65. PubMed ID: 25450818
[TBL] [Abstract][Full Text] [Related]
3. Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus.
Park JS; Cho MH; Nam JS; Yoo JS; Ahn CW; Cha BS; Kim KR; Lee HC
Eur J Endocrinol; 2011 Jan; 164(1):69-74. PubMed ID: 20961967
[TBL] [Abstract][Full Text] [Related]
4. Fat redistribution preferentially reflects the anti-inflammatory benefits of pioglitazone treatment.
Moon JH; Kim HJ; Kim SK; Kang ES; Lee BW; Ahn CW; Lee HC; Cha BS
Metabolism; 2011 Feb; 60(2):165-72. PubMed ID: 20092860
[TBL] [Abstract][Full Text] [Related]
5. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
6. Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes.
Gupta AK; Bray GA; Greenway FL; Martin CK; Johnson WD; Smith SR
J Diabetes Complications; 2010; 24(5):289-96. PubMed ID: 19577936
[TBL] [Abstract][Full Text] [Related]
7. Comparative effects of metformin and pioglitazone on YKL-40 in type 2 diabetes: a randomized clinical trial.
Esteghamati A; Rezvani S; Khajeh E; Ebadi M; Nakhjavani M; Noshad S
J Endocrinol Invest; 2014 Dec; 37(12):1211-8. PubMed ID: 25138574
[TBL] [Abstract][Full Text] [Related]
8. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.
Derosa G; Mereu R; D'Angelo A; Salvadeo SA; Ferrari I; Fogari E; Gravina A; Palumbo I; Maffioli P; Randazzo S; Cicero AF
J Clin Pharm Ther; 2010 Oct; 35(5):565-79. PubMed ID: 20831680
[TBL] [Abstract][Full Text] [Related]
9. Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study.
Hanefeld M; Pfützner A; Forst T; Kleine I; Fuchs W
Cardiovasc Diabetol; 2011 Jul; 10():65. PubMed ID: 21756323
[TBL] [Abstract][Full Text] [Related]
10. PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
Pfützner A; Schöndorf T; Tschöpe D; Lobmann R; Merke J; Müller J; Lehmann U; Fuchs W; Forst T
Diabetes Technol Ther; 2011 Jun; 13(6):637-43. PubMed ID: 21457065
[TBL] [Abstract][Full Text] [Related]
11. Comparative effects of metformin and pioglitazone on omentin and leptin concentrations in patients with newly diagnosed diabetes: a randomized clinical trial.
Esteghamati A; Noshad S; Rabizadeh S; Ghavami M; Zandieh A; Nakhjavani M
Regul Pept; 2013 Mar; 182():1-6. PubMed ID: 23328000
[TBL] [Abstract][Full Text] [Related]
12. Effects of early use of pioglitazone in combination with metformin in patients with newly diagnosed type 2 diabetes.
Chalmers J; Hunter JE; Robertson SJ; Baird J; Martin M; Franks CI; Whately-Smith CR; Mariz S; Campbell IW
Curr Med Res Opin; 2007 Aug; 23(8):1775-81. PubMed ID: 17712875
[TBL] [Abstract][Full Text] [Related]
13. Comparative effects of pioglitazone and metformin on oxidative stress markers in newly diagnosed type 2 diabetes patients: a randomized clinical trial.
Mirmiranpour H; Mousavizadeh M; Noshad S; Ghavami M; Ebadi M; Ghasemiesfe M; Nakhjavani M; Esteghamati A
J Diabetes Complications; 2013; 27(5):501-7. PubMed ID: 23891275
[TBL] [Abstract][Full Text] [Related]
14. Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot study.
Musholt PB; Schöndorf T; Pfützner A; Hohberg C; Kleine I; Fuchs W; Hehenwarter S; Dikta G; Kerschgens B; Forst T
J Diabetes Sci Technol; 2009 Nov; 3(6):1442-50. PubMed ID: 20144400
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea.
Liu SC; Chien KL; Wang CH; Chen WC; Leung CH
Endocr Pract; 2013; 19(6):980-8. PubMed ID: 23807528
[TBL] [Abstract][Full Text] [Related]
16. Effects of pioglitazone and metformin fixed-dose combination therapy on cardiovascular risk markers of inflammation and lipid profile compared with pioglitazone and metformin monotherapy in patients with type 2 diabetes.
Perez A; Jacks R; Arora V; Spanheimer R
J Clin Hypertens (Greenwich); 2010 Dec; 12(12):973-82. PubMed ID: 21122063
[TBL] [Abstract][Full Text] [Related]
17. The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus.
Erdem G; Dogru T; Tasci I; Bozoglu E; Muhsiroglu O; Tapan S; Ercin CN; Sonmez A
Diabetes Res Clin Pract; 2008 Nov; 82(2):214-8. PubMed ID: 18778865
[TBL] [Abstract][Full Text] [Related]
18. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
[TBL] [Abstract][Full Text] [Related]
19. Continuation or discontinuation of pioglitazone when starting bedtime insulin in patients with poorly controlled type 2 diabetes in an inner-city population.
Mojtahedzadeh M; Lee ML; Friedman TC
J Diabetes Complications; 2015; 29(8):1248-52. PubMed ID: 26215435
[TBL] [Abstract][Full Text] [Related]
20. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
Meneghini LF; Traylor L; Schwartz SL
Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]